Sign in

APUS on NYSE

Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Matawan, New Jersey.1 Its shares trade on NYSE under the symbol APUS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerAPUS on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMatawan, New Jersey1
  • Incorporated inDE2
  • Business address100 Matawan Rd, Suite 325, Matawan, Nj 077472
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

The Closing occurred simultaneously with the execution and delivery of the Merger Agreement on the Closing Date.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$11.9M in 2025+1494% since 2023
-$15.0M-$10.0M-$5.0M02023: -$747.4K-$747.4K20232024: -$1.3M-$1.3M2024+71%2025: -$11.9M-$11.9M2025+834%
Net income45-$6.0M in 2025+672% since 2023
-$8.0M-$6.0M-$4.0M-$2.0M02023: -$777.7K-$777.7K20232024: -$1.4M-$1.4M2024+79%2025: -$6.0M-$6.0M2025+332%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development expenses$1.6M
General and administrative expenses$10.3M$1.3M
Total operating expenses$11.9M$1.3M
Loss from operations-$11.9M-$1.3M
Unrealized gain from changes in fair value of digital assets$1.8M
Realized gain on sale of digital assets$4.2M
Trading gains, net$97
Foreign currency gains/(losses), net-$521
Change in FV of warrant liability$22.4K
Change in FV of derivative$55.1K
Interest income$107.6K$2.8K
Interest expense-$283.0K-$117.7K
Total other income (expense)$5.9M-$114.9K
Net loss-$6.0M-$1.4M
Net loss per common share - basic (in Dollars per share)-$0.55-$0.18
Net loss per common share - diluted (in Dollars per share)-$0.55-$0.18
Weighted average common shares outstanding - basic (in Shares)10.9M shares7.9M shares
Weighted average common shares outstanding - Diluted (in Shares) (in Shares)10.9M shares7.9M shares

Compare Apimeds Pharmaceuticals US, Inc. with another company

Corporate structure

Apimeds Pharmaceuticals US, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Apimeds Pharmaceuticals US, Inc.

  • Inscobee Inc. Filed SCHEDULE 13D/A on Apimeds Pharmaceuticals US, Inc., latest May 7, 2026 (5 filings since May 19, 2025)
  • Ayrton Capital LLC Filed SCHEDULE 13G on Apimeds Pharmaceuticals US, Inc., latest Feb 11, 2026
  • Apimeds Pharmaceuticals US, Inc. Matawan, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Apimeds Pharmaceuticals US, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$51.6K5 Dec 31, 2025
Operating-lease assets (leased space)$187.4K5 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.6M5 Dec 31, 2025$3.5K5 Dec 31, 2024+47270.6%
Marketable securities, current$2.0M5 Dec 31, 2025
Deposits held (banks)$8.0M5 Dec 31, 2025

Properties, in its own words

Our principal executive offices are located at 100 Matawan Rd, Suite 325, Matawan, New Jersey 07747. Our Digital Asset Treasury business operations are headquartered at 60 Paya Lebar Road #04-23, Singapore 409051.

We do not own any real property. We believe our current facilities are suitable for our current operations.

Item 2 of the 10-K filed May 4, 2026.3

Leadership

Who has led Apimeds Pharmaceuticals US, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Erik Emerson2025–now

Chief financial officer

  1. Mark Corrao2025–now
Board members and other officers (6)

Timeline

  1. Oct 13, 20268-K Other events15
  2. Oct 1, 20268-K Executive or director change16
  3. Sep 29, 20268-K Other events17
  4. Sep 23, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed18
  5. Sep 11, 20268-K Entered a material agreement; Executive or director change19
  6. Aug 21, 20268-K Entered a material agreement20
  7. Aug 6, 20268-K Other events21
  8. Jul 13, 20268-K Other events22
  9. May 5, 20268-K Executive or director change23
  10. May 4, 20268-K Entered a material agreement; Executive or director change; Other events24
  11. Apr 22, 20268-K Listing notice or transfer25
  12. Apr 16, 20268-K Other events26
  13. May 8, 2025New chief executive Erik Emerson becomes CEO8

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202627

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

127 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 28 major events, 35 insider forms, 6 large holders, 50 other. The latest 20:

  1. Oct 13, 20268-K CURRENT REPORT EDGAR
  2. Oct 1, 20268-K CURRENT REPORT EDGAR
  3. Sep 29, 20268-K CURRENT REPORT EDGAR
  4. Sep 23, 20268-K CURRENT REPORT EDGAR
  5. Sep 11, 20268-K CURRENT REPORT EDGAR
  6. Aug 21, 20268-K CURRENT REPORT EDGAR
  7. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  8. Aug 6, 20268-K CURRENT REPORT EDGAR
  9. Jul 13, 20268-K CURRENT REPORT EDGAR
  10. May 26, 202610-Q QUARTERLY REPORT EDGAR
  11. May 15, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  12. May 7, 2026SCHEDULE 13D/A EDGAR
  13. May 5, 20268-K CURRENT REPORT EDGAR
  14. May 4, 202610-K ANNUAL REPORT EDGAR
  15. May 4, 20268-K CURRENT REPORT EDGAR
  16. Apr 22, 20268-K EDGAR
  17. Apr 16, 20268-K CURRENT REPORT EDGAR
  18. Apr 9, 2026425 AMENDMENT NO. 1 TO FORM 8-K EDGAR
  19. Apr 9, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  20. Mar 31, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR

The 127 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 14, 2025Kim ChristopherChairman and CMOBuy7,730$1.86$14.4KForm 4
May 13, 2025Kim ChristopherChairman and CMOBuy19,770$1.82$36.0KForm 4
May 12, 2025Koo JakapDirectorBuy28,500$1.99$56.7KForm 4
May 12, 2025Inscobee Inc.10% ownerBuy500,000$4.00$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Apimeds Pharmaceuticals US, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARApimeds Pharmaceuticals US, Inc.1
  • CIK0001894525
  • Employer ID (EIN)85-10997003
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Matawan Rd, Suite 325, Matawan, NJ 077471
  • Phone848-201-50101
  • Shares outstanding1,509,118 as of Aug 12, 20267
  • Public float$7.8M as of Jun 30, 20253
  • AuditorKreit & Chiu CPA LLP, New York, New York PCAOB ID 6651; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJan 29, 20241
  • Filings127 in all: 8-K (25), 4 (22), 3 (9), CORRESP (8), S-1/A (7), UPLOAD (7), 10-Q (5), SCHEDULE 13D/A (4)1
    All 31 form types

    425 (3), 8-K/A (3), DRS/A (3), DRSLTR (3), NT 10-Q (3), POS AM (3), 10-K (2), 3/A (2), 4/A (2), EFFECT (2), NT 10-K (2), 10-K/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEFM14C (1), DRS (1), FWP (1), PREM14C (1), S-1 (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) May 4, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01APUSNYSE

From the cover page of the 10-K filed May 4, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

Legal proceedings

From time to time, we may be involved in legal proceedings, claims, or regulatory matters arising in the ordinary course of business. As of the date of this Annual Report, we are not a party to any material pending legal proceedings, nor are we aware of any such proceedings contemplated by governmental authorities.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
    SEC EDGAROther events
  16. 16
  17. 17
    SEC EDGAROther events
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29